| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. | Chief Strategy Officer | Common Stock | 2,655 | $10,885 | $4.10 | 10 Dec 2025 | Direct |
| Avalo Therapeutics, Inc. | Chief Strategy Officer | Stock Option (Right to Buy) | 95,000 | 26 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | 26 Feb 2026 | 1 | $0 | 4 | Chief Strategy Officer | 02 Mar 2026, 16:23 |
| AVTX | Avalo Therapeutics, Inc. | 10 Dec 2025 | 1 | -$2,612 | 4 | Chief Strategy Officer | 12 Dec 2025, 16:18 |
| AVTX | Avalo Therapeutics, Inc. | 01 Jan 2025 | 1 | $0 | 4 | Chief Strategy Officer | 03 Jan 2025, 16:06 |
| AVTX | Avalo Therapeutics, Inc. | 01 Jan 2025 | 0 | $0 | 3 | Chief Strategy Officer | 03 Jan 2025, 16:00 |